dc.contributor.author | Bjerknes, Christian | |
dc.contributor.author | Framroze, Bomi | |
dc.contributor.author | Currie, Crawford | |
dc.contributor.author | Pettersen, Caroline Hild | |
dc.contributor.author | Axcrona, Karol | |
dc.contributor.author | Hermansen, Erland | |
dc.date.accessioned | 2022-08-10T07:07:38Z | |
dc.date.available | 2022-08-10T07:07:38Z | |
dc.date.created | 2022-04-23T12:21:42Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1660-3397 | |
dc.identifier.uri | https://hdl.handle.net/11250/3010959 | |
dc.description.abstract | Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate cancer progression. A bioactive peptide-rich salmon protein hydrolysate (SPH) has previously been demonstrated to modulate iron homeostatic mechanisms. In the present study, the anticancer effect of SPH and bicalutamide co-treatment on LNCaP and PC3 prostate cancer cell proliferation was investigated. Our results found that SPH potentiates the anti-proliferative effect of bicalutamide in a dose-dependent manner for both cell lines. In the presence of 160 µg/mL SPH, co-treatment with 1.0 µM bicalutamide decreased LNCaP cells’ relative colony survival from 25% (1.0 µM bicalutamide monotreatment) to 2% after culturing for 12 days. For PC3 cells, the relative colony survival diminished from 52% (10.0 µM bicalutamide) to 32% at an SPH concentration of 160 µg/mL. Gene expression profiling, employing quantitative real-time PCR, revealed that the inhibitory effects were related to significant FTH1 up-regulation with a concomitant TFRC down-regulation. In conclusion, our results provide in vitro evidence that SPH potentiates the growth inhibitory effect of bicalutamide on prostate cancer cells by modulating iron homeostasis mechanisms. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 by the authors | en_US |
dc.source.articlenumber | 228 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/md20040228 | |
dc.identifier.cristin | 2018579 | |
dc.source.journal | Marine Drugs | en_US |
dc.identifier.citation | Marine Drugs. 2022, 20 (4), 228. | en_US |
dc.source.volume | 20 | en_US |
dc.source.issue | 4 | en_US |